MASLD affects more than 25% of subjects of the general population and can progress to advanced fibrosis (AF) and cirrhosis , especially in patients with type 2 diabetes (T2D). 

The study aimed to retrospectively assess the diagnostic performance of LIVERFASt fibrosis test against historically collected liver biopsy from a MASLD adult dataset from the National Institute of Diabetes and Digestive and Kidney Diseases central biorepository (NIDDK-CR).